Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SHILPAMED.NS
BuyPremium GrowerShilpa Medicare Limited · Healthcare · India · $2.0B · Avg Vol: $28M/d
69
StockRankGet insider-trade alerts
Q
63
V
17
M
83
P/E (TTM)
63.3x
ROE
9.4%
D/E
0.3x
Dividend %
0.1%
COMPANY DESCRIPTION
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.4B | 11.5B | 12.8B | 15.4B | 13.8% | 16.8B | 18.9B | 23.0B | 22.2% |
| EPS (INR) | -0.83 | 0.81 | 4.02 | 12.44 | 290.8% | 15.17 | 15.62 | 21.76 | 32.3% |
| Shares | 195.6M | 195.6M | 97.8M | 195.6M | 0.0% | 195.6M | — | — | — |
| Debt | 8.0B | 9.4B | 5.9B | 6.6B | -6.1% | 6.6B | — | — | — |
| Equity | 17.8B | 18.0B | 23.6B | 25.9B | 13.3% | — | — | — | — |
| Op CF | 1.8B | 1.4B | 1.3B | 3.4B | 23.9% | 3.4B | — | — | — |
| Inv CF | -2.3B | -1.7B | -2.0B | -3.3B | — | — | — | — | — |
| Fin CF | 458.0M | 467.7M | 626.5M | 136.2M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+59.4%
SMA 50SMA 200
Close
$10.10
RSI (14)
71.8
52W High
$10.31
From 52W High
1.0%
SCORE BREAKDOWN
Quality
63
ROIC
14.4%82.0
ROE
9.4%68.4
GP/Assets
31.5%66.2
Op. Margin
21.7%84.9
FCF/Assets
-0.8%43.4
Piotroski
783.9
Int. Cover
6.0x54.1
D/E Ratio
0.25x45.1
Current Ratio
1.31x20.5
Value
17
P/E (TTM)
63.3x16.1
EV/EBITDA
40.8x15.0
P/FCF
—N/A
P/B
7.3x18.0
P/S
11.2x24.2
Div Yield
0.1%2.9
Momentum
83
52W High %
98%98.4
RS 6M
190%99.1
SMA 50/200
1.56x98.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-31%12.7
Q Growth
115%85.2
FUNDAMENTALS
Market Cap
$2.0B
P/E (Forward)
92.1x
Gross Margin
69.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SHILPAMED.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SHILPAMED.NS | Shilpa Medicare Limited(you) | $2.0B | 69 | Buy |
| NATCOPHARM.NS | NATCO Pharma Limited | $1.6B | 72 | Buy |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| PPLPHARMA.NS | Piramal Pharma Limited | $3.2B | 58 | Hold |
| AARTIPHARM.NS | Aarti Pharmalabs Limited | $829M | 65 | Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%